As well as reducing activity toward RAS, switching isoforms to NF1-II in HGG will therefore reduce the ability of tumor cells to dampen their response to constitutive pathway activation as well as ligand-mediated signaling through other receptors. The gene discussed is NF1; the disease is neoplasm.